Our Team

Andrew Altschuler is the Founder, Chairman, President and Chief Executive Officer of GOA Therapeutics. A serial entrepreneur with more than 30 years of business experience, Andrew founded GOA Therapeutics with the vision to build the GOAT — the Greatest of All Therapeutics Companies — by pioneering first-in-class, transformative medicines for the most significant unmet medical needs and building a world-class company that creates a profound and lasting impact on human health.

As Founder and CEO, Andrew spent years developing the vision for GOA Therapeutics and laying the foundation and groundwork upon which the Company was built. From its earliest stages, he has led the development of GOA from concept to an emerging biopharmaceutical company, assembling a multidisciplinary team of scientists, physicians, drug-development executives and industry leaders and building the scientific, intellectual property, regulatory, medical and commercial infrastructure required to advance the Company’s therapeutic programs. He leads GOA’s corporate strategy, financing, business development and capital-markets activities and works closely with the Company’s scientific and medical leadership to guide its long-term development.

Throughout his entrepreneurial career, Andrew has demonstrated a strong ability to identify new opportunities, build companies from the ground up and guide ventures through significant growth. Andrew has founded businesses across an unusually diverse range of industries, including biotechnology, fintech, e-commerce and technology, commodities and global trade, real estate and hospitality, manufacturing, consumer goods, marketing, wholesale distribution and retail, jewelry and precious stones and metals. He is also the sole named inventor on multiple issued patents in the fields of e-commerce and financial technology.

Earlier in his career, Andrew worked as a Certified Public Accountant at KPMG and in mergers and acquisitions advisory at Salomon Smith Barney. He also worked in wealth management at Merrill Lynch and completed his accounting internship at Arthur Andersen. This foundation in accounting, investment banking and financial advisory, combined with three decades as an entrepreneur and operator, has shaped his approach to building businesses.

Andrew has been a licensed Certified Public Accountant since 1998. He earned a BBA in Accounting and an MPA in Financial Information Systems, both from The University of Texas at Austin.

Dr. Tami Ehrmann Barr is Co-Founder, Chief Scientist and a member of the Board of Directors of GOA Therapeutics. A multidisciplinary physician-scientist, inventor and biotechnology executive with more than 40 years of experience, she has devoted her career to identifying promising scientific opportunities and translating them into innovative therapeutics, technologies and products.

Dr. Ehrmann Barr is the scientific architect behind GOA Therapeutics. Before co-founding the Company, she spent more than a decade conducting the drug discovery and research that ultimately formed GOA’s scientific foundation, with a primary focus on protein engineering, particularly the engineering and optimization of therapeutic enzymes, together with the chemistry, formulation and development of combination therapeutic approaches. This work laid the scientific groundwork for GOA’s technology and therapeutic programs. As Chief Scientist, she leads the Company’s scientific strategy, drug discovery and research and development, working across disciplines to advance its therapeutic pipeline.

Throughout her career, Dr. Ehrmann Barr has held senior scientific and executive leadership positions across pharmaceuticals, biotechnology, medical devices, agrotechnology and advanced technologies, including roles as Chief Scientific Officer, Chief Operating Officer, Chief Technology Officer, President and Head of Research and Development. Her leadership experience has included companies that are now publicly traded, including Nano Dimension, Can-Fite Biopharma, RDD Pharma and ADAMA, as well as numerous emerging biotechnology and medical technology ventures. Her career has also included scientific and development programs involving leading global pharmaceutical companies, including Teva, Novo Nordisk and Ciba-Geigy, now Novartis. Her work has spanned drug discovery and development, biotechnology, clinical development, regulatory strategy, medical devices, drug-delivery technologies and bioprinting, with programs progressing from early scientific concepts through development, clinical evaluation and commercialization.

Dr. Ehrmann Barr is an inventor on numerous patents and patent applications spanning pharmaceuticals, biotechnology, bioprinting, drug delivery, nutraceuticals and medical technologies. Throughout her career, she has demonstrated an ability to integrate scientific disciplines, identify novel applications for emerging technologies and build multidisciplinary development programs around them.

Dr. Ehrmann Barr earned her BSc in Chemistry from The Hebrew University of Jerusalem and her MSc in Chemical Engineering and Medical Engineering from Ben-Gurion University of the Negev in collaboration with Soroka Hospital. She earned her PhD in Biotechnology and Microbiology from The Hebrew University of Jerusalem’s Otto Warburg Institute for Biotechnology in collaboration with the Max Planck Institute in Cologne, Germany, where she subsequently completed postdoctoral research in protein engineering. She earned her MD from the University of Cologne and also holds an LLB from Ono Academic College.

Dr. Dean Hakanson is Chief Medical Officer of GOA Therapeutics, where he leads the Company’s medical affairs and medical strategy and plays a central role in shaping the scientific, clinical and commercial development of GOA’s therapeutic programs. Dr. Hakanson oversees GOA’s Drug Development Board, publication strategy, scientific congress strategy, medical communications and engagement with the clinical and scientific communities. As one of the Company’s principal medical spokespeople, he also plays a key role in communicating GOA’s science externally and will be closely involved in market preparation and commercialization.

Dr. Hakanson brings more than 25 years of leadership experience across medical affairs, health economics and outcomes research, market access, clinical development and commercialization. He previously served as Vice President and Head of U.S. Medical Affairs at Gilead Sciences, where he helped lead the U.S. medical affairs effort supporting the rollout of remdesivir during the COVID-19 pandemic. Earlier in his career, Dr. Hakanson served as Vice President and Head of Health Economics and Outcomes Research for U.S. Medical and Drug Regulatory Affairs at Novartis, Vice President of Healthcare Access at Bristol-Myers Squibb, and Head of the Value-Based Healthcare/Payer Field Team at Genentech. He also held multiple senior leadership positions at GlaxoSmithKline and has served as Chief Medical Officer of Otonomy and COEUS and as a Partner at ZS Associates.

Throughout his career, Dr. Hakanson has worked at the intersection of medicine, evidence generation, medical affairs, market access and commercialization. This multidisciplinary experience provides GOA with medical leadership extending from drug development and scientific communication through market preparation, physician engagement and the potential introduction of new therapies into clinical practice.

Dr. Hakanson earned his bachelor’s degree in Cellular Physiology and Physics from the University of Denver and his MD from the University of Colorado School of Medicine. He subsequently completed postgraduate medical training at the University of Michigan. Dr. Hakanson is board certified in anesthesiology and practiced anesthesiology and critical care medicine before transitioning to the biopharmaceutical industry.

Dr. Scott Howell is Chief Commercial Officer at GOA Therapeutics, where he leads the Company’s commercial strategy, market access, health economics and outcomes research (HEOR), and commercialization planning.

Dr. Howell brings more than 30 years of experience spanning clinical medicine, biopharmaceuticals, managed care, market access, specialty pharmaceuticals and healthcare strategy. Most recently, he served as Chief Strategy Officer for U.S. Pharmaceuticals at Novartis and as a member of the U.S. Pharmaceuticals Executive Committee. He previously served as Vice President and Head of U.S. Market Access at Novartis, with responsibility for pricing and contracting, channel management, managed care, hospital systems, and patient and specialty services.

Prior to Novartis, Dr. Howell served as Vice President of Market Access at Jazz Pharmaceuticals and as Senior Vice President of Clinical Services at Cardinal Health Specialty Solutions. Earlier in his career, he held leadership roles at Genentech spanning market access and clinical development, served as Vice President of Pharmacy Affairs at Highmark Blue Cross Blue Shield, and held medical affairs and managed care leadership positions at GlaxoSmithKline.

Dr. Howell is a nationally recognized expert and thought leader in pharmaceutical market access, drug pricing, payer strategy, reimbursement, affordability and patient access. He co-hosts Prescription for Better Access, a podcast focused on the complex issues surrounding U.S. drug pricing, coverage, reimbursement and patient access. He has taught, researched and written on pharmaceutical pricing and access for more than 15 years, including work at the University of California, Berkeley, and is a frequent speaker and commentator on the evolving economics of the U.S. pharmaceutical market.

At GOA, Dr. Howell brings this multidisciplinary experience to the development of the Company’s commercial strategy, including market access, pricing and reimbursement, payer engagement, health economics, evidence generation and commercialization planning.

Dr. Howell earned his undergraduate degree from the University of Notre Dame and his MD from The Ohio State University. He completed his medical internship and residency and earned his MBA from Duke University.

David Landesman is Chief Operating Officer of GOA Therapeutics, where he builds and runs the company’s operational backbone: information technology, communications architecture, enterprise systems, and the infrastructure supporting the company’s growth and financing activities.

A software engineer by background with over 18 years in engineering, system architecture, and technical strategy, David brings a systems-first approach to operations, pairing lean teams with AI-powered tooling and automation to drive velocity without adding headcount.

Over his career he has held senior leadership roles at technology companies, including Chief Technology Officer.

Dr. Iris Tam is Head of Medical Affairs & Health Economics and Outcomes Research (HEOR) at GOA Therapeutics, bringing 35 years of experience across medical affairs, market access, HEOR, managed care and clinical pharmacy.

Dr. Tam has held senior Medical Affairs leadership positions at Genentech, Otonomy and Achaogen, with responsibilities spanning health economics and outcomes research, medical communications, evidence generation, payer engagement, formulary and compendia strategy, and patient access. She previously served as Senior Vice President of Medical Affairs & HEOR at COEUS, where she led a business unit focused on evidence synthesis, HEOR strategy and payer communications.

Dr. Tam has been an active leader within the Academy of Managed Care Pharmacy (AMCP), including more than a decade of service on the AMCP Format Executive Committee, and is a Fellow of the Academy of Managed Care Pharmacy. She has also received AMCP’s Spirit of Volunteerism Award for her contributions to the profession.

Dr. Tam earned her Doctor of Pharmacy from the University of California, San Francisco and her bachelor’s degree in Microbiology and Immunology from the University of California, Berkeley. She subsequently completed residencies in Clinical Pharmacy Practice and Pharmacy Administration at California Pacific Medical Center in San Francisco.

Jaron Gilinsky is Vice President of Marketing at GOA Therapeutics, where he leads the Company’s marketing, brand storytelling, content strategy and digital communications. He shapes how GOA communicates its science, mission and vision across audiences, including patients, healthcare professionals, investors and the broader public.

An entrepreneur, award-winning journalist and media executive, Jaron brings more than 20 years of experience in storytelling, digital media, content strategy and brand communications. Before joining GOA, he founded Storyhunter (now Glimmer), a global platform connecting organizations with creative professionals and production resources around the world, and served as its CEO for more than a decade. At Storyhunter, Jaron worked with Fortune 500 companies and their C-level marketing and brand leadership teams to develop and execute content strategies, while building and leading a global business centered on content creation, creative talent and digital storytelling.

Earlier in his career, Jaron worked internationally as a video journalist and documentary filmmaker, including assignments for The New York Times, TIME and Current TV. His reporting took him across the Middle East and other regions of the world, and his journalism has been recognized by the Overseas Press Club.

At GOA, Jaron combines his background in journalism, entrepreneurship and digital media with a strategic approach to marketing and communications. He develops compelling narratives, strengthens the Company’s brand and oversees content and digital initiatives that support GOA’s growth and engagement with its key audiences. Jaron graduated summa cum laude from the University of Florida with a BA in International Relations.

Luke Downey, PhD is Professor of Neurocognition at Swinburne University and an adjunct Research Fellow at the Institute of Breathing & Sleep, Austin Hospital. He received his PhD in Psychology in 2010, then undertook postdoctoral research at Swansea University in 2013-2014, and completed further training in addiction medicine in 2015 as a visiting scholar at Harvard Medical School. Professor Downey has developed a substantial international publication record, with more than 150 peer-reviewed publications focused on alcohol, cannabis, and other psychoactive substances, with a particular emphasis on understanding how these substances affect cognition, behaviour, visual attention and driving performance. He has accrued career funding exceeding $10 million including consecutive early-career and career-development fellowships from Australia’s National Health and Medical Research Council and received competitive grant funding from State and Federal Government bodies for research in human psychopharmacology.

Dr. Catherine Juillard is a member of GOA Therapeutics’ Drug Development Board and a nationally recognized trauma surgeon and surgical critical care physician with extensive clinical, academic and research experience.

Dr. Juillard is Professor of Surgery at the David Geffen School of Medicine at UCLA and holds the Marjorie Fine, MD, Endowed Chair in Clinical General Surgery. She also serves as Director of UCLA’s Trauma/Surgical Critical Care Fellowship and has held leadership positions focused on trauma care, surgical equity and injury prevention.

Prior to joining UCLA, Dr. Juillard was on the faculty at the University of California, San Francisco, where she served as Director of the Center for Global Surgical Studies and Director of the San Francisco Wraparound Project. Her research has focused extensively on trauma systems, surgical health disparities, injury prevention and improving access to high-quality trauma and surgical care.

Dr. Juillard earned her undergraduate degree from Stanford University and her MD from UCLA. During her general surgery residency at UCLA, she earned an MPH from the Johns Hopkins Bloomberg School of Public Health and completed a postdoctoral fellowship with the Johns Hopkins International Injury Research Unit. She subsequently completed fellowship training in Trauma and Surgical Critical Care at UCSF.

Caleb Butts MD is a board-certified trauma surgeon and surgical intensivist with extensive experience caring for critically ill and injured patients in high-acuity trauma and intensive care settings. He brings more than a decade of clinical leadership across trauma surgery, critical care, and emergency surgical services, with deep expertise in resuscitation, critical illness, and systems-based trauma care. Dr. Butts brings a frontline, systems-level perspective to research and clinical development, informed by more than a decade of hands-on experience in resuscitation, critical care, and protocol-driven trauma management. He has led and participated in numerous clinical investigations, quality initiatives, and guideline implementation efforts, with a focus on outcomes, safety, and efficient care delivery in complex hospital settings.

Dr. Butts earned his MD from the University of South Alabama College of Medicine and completed residency training in general surgery, followed by fellowships in surgical critical care and acute care surgery at Wake Forest Baptist Medical Center. As a member of a research advisory board, Dr. Butts provides practical guidance on clinical trial design, patient selection, endpoints, feasibility, and real-world adoption within emergency department, trauma, and ICU workflows.

Dr. Stephanie N. Lueckel, MD, ScM, FACS, is Professor of Surgery and Chief of Trauma, Acute Care Surgery, and Surgical Critical Care at Brown University and Rhode Island Hospital. She is a trauma surgeon, surgical intensivist, educator, researcher, and healthcare leader with more than a decade of experience advancing trauma care, critical care, surgical education, and patient-centered communication. In addition to her clinical and academic roles, she serves as Associate Surgeon-in-Chief at Rhode Island Hospital and President of the Lifespan Medical Executive Committee. Throughout her career, she has received numerous awards for teaching excellence and leadership and has mentored countless medical students, residents, and fellows.

Outside of medicine, Stephanie is the proud single mother of three children, two of whom have special needs. Her experiences as both a physician and caregiver have shaped her commitment to compassion, advocacy, resilience, and teamwork. She is passionate about building supportive communities, fostering meaningful connections, and learning from those around her. She is excited to join and work with this group and looks forward to contributing her experience while learning from her colleagues.

Dr. Steven Shoptaw is a member of GOA Therapeutics’ Drug Development Board and an internationally recognized researcher in addiction science, substance-use disorders and the development of pharmacologic and behavioral interventions for addiction.

Dr. Shoptaw is a licensed psychologist and Professor Emeritus of Family Medicine at the David Geffen School of Medicine at UCLA, where he serves as Vice Chair for Research in the Department of Family Medicine. He is also Executive Director of UCLA’s Center for Behavioral & Addiction Medicine and has held appointments in Psychiatry and Biobehavioral Sciences.

For more than 25 years, Dr. Shoptaw has led clinical research focused on developing and evaluating treatments for substance-use disorders. He has served as Principal or Co-Investigator on more than 40 research projects, primarily funded by the National Institutes of Health, and has extensive experience conducting clinical trials of pharmacologic and behavioral interventions for addiction. His expertise in addiction science and the clinical study of substance-use disorders provides GOA with important perspective on the development of novel treatments addressing the medical and public-health consequences of alcohol use.

Dr. Shoptaw earned his BA, MA and PhD in Psychology from UCLA and completed postdoctoral training in Psychophysiology at UCLA.

Dr. Vicki Norton is a community emergency physician in Florida and a partner in one of the few independent, physician-owned democratic groups in the state. She has served as clinical affiliate faculty for Florida Atlantic University since 2021 and enjoys teaching and mentoring medical students.

Dr. Norton graduated from the University of North Carolina at Chapel Hill in 2001 with a B.S. in Biology. From there, she conducted research under Dr. Frank Longo, chair of the Department of Neurology at UNC, studying genes that could play a role in the development of Alzheimer’s disease. She left North Carolina in 2003 to start medical school at Drexel University College of Medicine, graduating in 2007. She completed her emergency medicine residency at Temple University Hospital in Philadelphia, PA, in 2010. After residency, she moved to Florida and began working as an emergency medicine attending. She served as President of the Florida Chapter Division of the American Academy of Emergency Medicine (AAEM) from 2017 to 2019 before joining AAEM’s national Board of Directors in 2020, where she rose through the organization’s leadership ranks to become President in 2026.

After seeing and experiencing firsthand the treatment of emergency physicians employed by corporate staffing groups, she became more involved in AAEM in order to better advocate for herself and her colleagues. She has worked as a national physician advocate, focused on protecting physician autonomy, strengthening physician-led care, and addressing the effects of healthcare consolidation and corporatization on patients and physicians. Through her leadership in the American Academy of Emergency Medicine, the Palm Beach County Medical Society, and organized medicine at the state and national level, she has helped advance policy reforms addressing the corporate practice of medicine, private equity in healthcare, emergency physician due process, safe staffing and supervision, emergency department boarding, medical staff self-governance, and transparency in physician employment and billing. Her recent research has complemented this advocacy by examining emergency physician productivity and supervision practices and the workforce consequences of emergency department boarding, including burnout, workplace violence, moral injury, and job dissatisfaction.

She is married with three children and enjoys cooking, baking, and traveling.

Dr. Bryan Loy is a member of GOA Therapeutics’ Drug Development Board and an experienced physician executive with expertise spanning managed care, payer strategy, oncology, laboratory medicine, personalized medicine and healthcare quality.

Dr. Loy has held senior medical leadership positions at Humana, where he has led initiatives in oncology, laboratory and personalized medicine. He brings extensive experience evaluating pharmaceuticals, biologics, medical devices and diagnostic technologies, with a particular focus on clinical evidence, healthcare quality, value and coverage considerations.

Dr. Loy is board certified in Anatomic and Clinical Pathology and Hematology. He has served as a clinical laboratory advisor to the Centers for Medicare & Medicaid Services (CMS) and has participated in steering committees and advisory groups involving organizations including the National Quality Forum, American Cancer Society and National Comprehensive Cancer Network.

His experience at the intersection of medicine, health insurance, evidence evaluation and reimbursement provides GOA with an important payer and market-access perspective as the Company advances its therapeutic programs toward commercialization. Dr. Loy earned his MD from the University of Louisville School of Medicine and holds an MBA.

Dr. Chudnofsky is Professor and Chair of the Department of Emergency Medicine at the Keck School of Medicine of USC in Los Angeles. He graduated from the George Washington University School of Medicine and Health Sciences in 1985 and did his emergency medicine training at the University of Cincinnati, where he was Chief Resident from 1988-1989. Dr. Chudnofsky served on the Board of Directors of the American Board of Emergency Medicine from 2014 to 2022, serving as Editor and Chief Examiner for the Oral Examination, and Chair of the Test Administration Committee. Dr. Chudnofsky’s administrative passion lies in ED operations, and his research interest has focused on improving procedural sedation in the ED.

Michelle Jones is Head of Government Affairs at GOA Therapeutics, bringing more than 20 years of experience in government affairs, public policy, healthcare advocacy and strategic engagement.

Michelle has held senior government affairs leadership positions within the pharmaceutical and healthcare industries, including at Adapt Pharma and Emergent BioSolutions. Her experience includes helping advance public policy and advocacy initiatives surrounding NARCAN® Nasal Spray and expanding access to opioid-overdose treatment across the United States.

Throughout her career, Michelle has worked with state governments, policymakers, healthcare organizations, advocacy groups and other stakeholders to navigate complex healthcare policy environments and advance initiatives addressing significant public health challenges. In recognition of her work, she was named Government Affairs Person of the Year at Emergent BioSolutions.

Her experience in substance-use policy and building coalitions among government, healthcare and community stakeholders provides particularly relevant expertise as GOA works to address the significant public health burden associated with acute alcohol intoxication and poisoning. Michelle earned her Master of Social Work from Florida Atlantic University.

David B. Nash, MD, MBA, is a healthcare leader with an unparalleled record of advancing population health and driving organizational success. Following a distinguished 35-year career at Thomas Jefferson University in Philadelphia, he now serves as Principal of
David B. Nash, MD, MBA, LLC.
Drawing on decades of leadership in academic medicine, governance, health policy, quality improvement, and business strategy, Dr. Nash advises healthcare organizations, boards, investors, and companies seeking experienced strategic guidance.

Dr. Nash was the Founding Dean of the Jefferson College of Population Health—the first college of its kind in the nation—and served as the
Dr. Raymond C. and Doris N. Grandon Professor of Health Policy. A board-certified internist, he is internationally recognized for his work in public accountability for outcomes, physician leadership development, and quality improvement.

He brings extensive governance experience across the public, nonprofit, and private sectors. Dr. Nash served as a hospital trustee for 20 years, including on the Board of Trustees of Catholic Healthcare Partners (now Mercy Health) in Cincinnati, Ohio, from 1998 to 2008, where he was the inaugural chair of the Quality and Safety Committee. He later served on the board of Main Line Health, a four-hospital system in suburban Philadelphia, from 2009 to 2017, and also chaired its Quality and Safety Committee. He currently serves on the board of the Geisinger Commonwealth School of Medicine.

In the for-profit sector, Dr. Nash completed nearly a decade as a member of the Board of Directors of Humana Inc., one of the nation’s largest publicly traded healthcare companies. For a dozen years, he has been an advisor to Arsenal Capital Partners in New York City and recently completed his tenure on the board of MaxHealth, an Arsenal portfolio company. He is also a board member of FOX Rehabilitation, a portfolio company of Blue Wolf Capital. In addition, he advises more than a dozen companies across the healthcare industry, bringing practical expertise in strategy, governance, quality, population health, value-based care, and health system transformation.

Dr. Nash’s work is widely recognized through his publications, speaking engagements, and 17-year tenure as a columnist for MedPage Today. He has authored more than 100 peer-reviewed articles and edited 25 books, including The Healthcare Quality Book, Demand Better, and his most recent best-selling title, How Covid Crashed the System: A Guide to Fixing American Healthcare.

He earned a BA in Economics, Phi Beta Kappa, from Vassar College; an MD from the University of Rochester School of Medicine and Dentistry; and an MBA in Health Administration, with honors, from the Wharton School of the University of Pennsylvania. While at Penn, he was a Robert Wood Johnson Foundation Clinical Scholar and Medical Director of a nine-physician faculty group practice in general internal medicine. Dr. Nash has delivered numerous endowed and named lectures throughout the United States and internationally.

Dr. Nash lives in Ardmore, Pennsylvania, with his wife of 45 years, Esther J. Nash, MD. They have three adult children and three grandchildren. He enjoys tennis, swimming, and biking. Together, they have endowed an annual healthcare quality and safety prize for learners across Jefferson. Established in 2021, the award was the first of its kind in the nation.

Dr. Rotem Perry Feigenbaum is Head of Bioanalytics at GOA Therapeutics, bringing extensive experience in analytical chemistry, bioanalytics and pharmaceutical research and development.

Dr. Perry Feigenbaum has held senior scientific and laboratory leadership positions spanning analytical and bioanalytical research, with extensive experience in the development and application of advanced analytical methodologies supporting pharmaceutical and biomedical research. At GOA, Dr. Perry Feigenbaum leads bioanalytical activities supporting the Company’s preclinical and drug development programs.

Dr. Perry Feigenbaum earned her PhD, MSc and BSc from Tel Aviv University. Her doctoral research in organic chemistry focused on the design and synthesis of novel molecular systems for diagnostic and medicinal applications.

Dr. Alaa Talhami is Director of Bioanalytics at GOA Therapeutics, bringing extensive experience in pharmaceutical development, bioanalytics, analytical chemistry and organic and medicinal chemistry.

Dr. Talhami has held scientific and pharmaceutical development positions with Teva Pharmaceutical Industries, NeuroDerm and Taro Pharmaceutical Industries. His industry experience spans analytical research and development, pharmaceutical characterization, formulation and drug development. His work has contributed to the development of novel pharmaceutical products, and he is an inventor on multiple pharmaceutical patents.

Dr. Talhami’s scientific research has encompassed organic and peptide chemistry, targeted drug-delivery systems and the design and development of novel therapeutic compounds. He has authored peer-reviewed scientific publications in organic, medicinal and pharmaceutical chemistry.

Dr. Talhami earned his PhD in Organic Chemistry from The Hebrew University of Jerusalem, where his doctoral research included the development of targeted drug-delivery systems for cancer therapeutics. He subsequently conducted postdoctoral research at The Hebrew University of Jerusalem focused on the design and development of cyclic peptide drug candidates with improved pharmacological properties.

Dmitry Soltin is a Bioanalytical Scientist at GOA Therapeutics, supporting the Company’s bioanalytical and drug development programs.

Dmitry is an analytical chemist with experience in laboratory-based analytical testing and the application of advanced analytical methodologies, including high-performance liquid chromatography (HPLC), for the characterization and quantitative analysis of pharmaceutical and biological samples. At GOA, Dmitry supports the development and execution of bioanalytical methods used throughout the Company’s preclinical research and development programs.

Dmitry holds an MSc in Chemical Engineering from the Belarusian State Technological University in Minsk, Belarus.

Dr. Maria Beatrice Panico is Medical Director at GOA Therapeutics, bringing extensive experience spanning clinical development, drug safety, neuroscience and global regulatory affairs.

Dr. Panico previously served as a Leading Senior Medical Assessor at the UK Medicines and Healthcare products Regulatory Agency (MHRA), where she represented the United Kingdom in European working groups focused on clinical trial design and safety. She has also contributed to international regulatory initiatives, including work with the World Health Organization.

Prior to joining the MHRA, Dr. Panico held pharmaceutical industry positions with Novartis Pharma in Switzerland and Servier in Italy, with responsibilities spanning European and Italian pharmacovigilance and drug safety. Earlier in her career, she practiced as a clinical neurologist and worked as a clinical investigator and neuroscience researcher.

Dr. Panico is the recipient of the 2023 TOPRA Lifetime Achievement Award for Regulatory Excellence. She earned her medical degree from the Catholic University of Rome, completed her specialization in neurology at the University of Rome Tor Vergata, and received her PhD in Neuroscience from the University of Rome Tor Vergata.

Ian Waterson is Head of Nonclinical Development at GOA Therapeutics, bringing more than 29 years of experience in drug development, toxicology and nonclinical regulatory science.

Ian spent eight years with the UK Medicines and Healthcare products Regulatory Agency (MHRA), including as a Senior Non-Clinical Assessor, where he was responsible for the regulatory assessment of nonclinical development programs. Earlier in his career, he held senior scientific and toxicology roles at Sanofi and Covance, with experience spanning drug safety evaluation, toxicology and nonclinical development.

At GOA, Ian provides scientific and regulatory leadership for the Company’s nonclinical development program as it advances toward clinical development. Ian holds an MSc in Applied Toxicology from the University of Surrey and a BSc (Hons) in Life Sciences from Napier University in Edinburgh.

Dr. Babaji Yadav is Principal Toxicologist at GOA Therapeutics, bringing extensive experience in nonclinical drug development, toxicology and early-phase clinical development.

Dr. Yadav has more than 18 years of combined academic and industry experience, with expertise spanning preclinical research, IND-enabling toxicology, regulatory strategy and the advancement of novel therapeutics into first-in-human clinical trials. His experience includes positions with Sanofi-Aventis, Kazia Therapeutics, IQVIA and Novotech, as well as extensive work advising biotechnology and pharmaceutical companies on global drug-development programs.

Dr. Yadav is a registered toxicologist in the United Kingdom and European Union and serves as an independent reviewer toxicologist on the Bellberry Human Research Ethics Committee in Australia. He holds a Ph.D. in Pharmacology and Toxicology from the University of Otago in New Zealand, as well as master’s and bachelor’s degrees in pharmacy.

Dr. James Parsley is Head of CMC at GOA Therapeutics, bringing more than 20 years of pharmaceutical industry experience in Chemistry, Manufacturing and Controls (CMC), biopharmaceutical development and regulatory affairs.

A former Director at GSK, Dr. Parsley has extensive experience developing global CMC strategies and guiding biologic products from early-stage development through regulatory approval and post-marketing. His expertise spans biopharmaceutical manufacturing, product characterization, control strategies and the regulatory requirements governing the development and manufacture of biologic therapeutics.

At GOA, Dr. Parsley provides strategic CMC leadership supporting the development, manufacturing and regulatory advancement of the Company’s therapeutic programs. Dr. Parsley holds a PhD in Biochemistry from the University of Sussex.

Dr. Raphael Mayer is an accomplished biochemist and biotechnology executive with extensive experience in assay development, bioanalytical research, and preclinical drug development.

His experience includes CEO of Smart Assay and Head of the Assay Development at Quark Biotechnology, where he has gained extensive expertise developing and implementing sophisticated biological assays in support of drug discovery and development programs.

Dr. Mayer has a strong academic foundation in biological chemistry and biochemistry and has contributed to peer-reviewed scientific research in cellular and molecular biology.

He earned his PhD in Biological Chemistry from the Hebrew University of Jerusalem and subsequently completed postdoctoral training at The Rockefeller University in New York.

Dr. Asha Kattige is Director of CMC & Regulatory Affairs at GOA Therapeutics, bringing more than 25 years of global pharmaceutical industry experience in Chemistry, Manufacturing and Controls (CMC), product development and regulatory affairs.

Dr. Kattige has held senior positions at UCB, Teva, Quotient Sciences and Patheon, with extensive experience developing and executing CMC and regulatory strategies to advance pharmaceutical products through clinical development and toward global regulatory approval. Her experience spans small molecules, biologics, proteins and peptides across multiple therapeutic areas.

At GOA, Dr. Kattige provides CMC and regulatory expertise supporting the development, manufacturing and regulatory advancement of the Company’s therapeutic programs. Dr. Kattige holds a PhD in Pharmaceutical Formulation and Technology from the University of Sunderland and a Master of Pharmacy in Pharmaceutical Formulation and Technology from the University of Mumbai.

Shmulik Tal is a Doctor of Veterinary Medicine and Preclinical Research Veterinarian at GOA Therapeutics, supporting the design and execution of the Company’s preclinical research program.

He brings extensive experience in veterinary medicine and preclinical research, including the conduct of in vivo studies and evaluation of investigational therapies in preclinical models. At GOA, Shmulik contributes veterinary and research expertise to the advancement of the Company’s preclinical development programs and their progression toward clinical development.

Shmulik received his Doctor of Veterinary Medicine from the University of Liverpool.

Dr. Zina Spero is a veterinarian and preclinical research scientist with extensive experience in the design and execution of preclinical studies supporting the development of novel therapeutics and medical technologies.

At GOA Therapeutics, Dr. Spero supports the Company’s preclinical research program, contributing scientific and veterinary expertise to the design, execution and evaluation of in vivo studies and the advancement of GOA’s therapeutic programs toward clinical development.

Dr. Spero received her Doctor of Veterinary Medicine from The Hebrew University of Jerusalem.

Phillip Brictson is Creative Director at GOA Therapeutics, responsible for the development and execution of the Company’s visual identity and creative direction across digital, print and corporate communications.

Phillip is an experienced brand identity designer specializing in the development of distinctive visual identities and cohesive brand systems. His work spans brand strategy, identity design, typography, digital design and the creation of visual systems that translate complex organizations and ideas into clear and compelling communications.

At GOA, Phillip helps shape how the Company and its science are presented visually across the corporate website, presentations, investor and scientific communications, and other internal and external materials. Phillip holds a bachelor’s degree in design from Illinois State University.

Emma Hawke is Regulatory Manager at GOA Therapeutics, supporting the coordination and execution of the Company’s drug development and regulatory programs.

Emma brings more than 15 years of experience in clinical research and project management across pharmaceutical, CRO, healthcare and academic environments. Her experience includes roles with ICON, IQVIA, Premier Research, the UK National Health Service (NHS) and the University of Southampton.

At GOA, Emma works across internal and external teams to coordinate development activities, regulatory workstreams, timelines and deliverables as the Company advances its therapeutic programs toward clinical development.

Emma holds a Master of Arts in Biomedical and Healthcare Ethics from the University of Leeds and a Bachelor of Science in Physiotherapy from the University of Southampton.